RxDoctor Payments Data

Benjamin Yu, MD

Psychiatry · Roseville, CANPI 1972617546

Payments from drug & device makers

$14,607in general payments, 2019–2025

Across 172 payments — averaging $84.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$11K
  • Tris Pharma Inc$2K
  • Otsuka America Pharmaceutical, Inc.$362
  • Vanda Pharmaceuticals Inc.$258
  • Takeda Pharmaceuticals U.S.A., Inc.$173
  • AbbVie$168
  • plus $815 from 13 others

What the payments were for

  • Speaking & faculty fees$8,21556%
  • Travel & lodging$1,55211%
  • Food & beverage$4,83733%
  • Education$40%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,607 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$9,640
Medicare patients
27
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$26,738
VraylarCariprazine Hcl15$22,635
Aripiprazole42$4,907
Lamotrigine ErLamotrigine15$4,466
Paliperidone ErPaliperidone18$3,125
Chlorpromazine Hcl23$3,012
Lurasidone Hcl18$2,934
Fluvoxamine Maleate17$2,092
Divalproex Sodium ErDivalproex Sodium30$1,973
Clozapine29$1,443
Quetiapine Fumarate21$1,313
Divalproex Sodium25$1,104
Trazodone Hcl57$1,072
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine17$1,043
Olanzapine65$1,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$168$22,63515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →